CareDx, Inc (NASDAQ: CDNA) Investor Investigation Concerning Potential Securities Laws Violations Announced

Investors who purchased shares of CareDx, Inc (NASDAQ: CDNA), have certain options and should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to, or call us at (858) 779-1554.
Company Name(s): 
Affected Securities: 

An investigation on behalf of investors of CareDx, Inc (NASDAQ: CDNA) shares over potential securities laws violations by CareDx, Inc and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of CareDx, Inc (NASDAQ: CDNA) concerning whether a series of statements by CareDx, Inc (regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Brisbane, CA based CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide.
In 2017, CareDx, Inc launched its AlloSure product for kidney transplant recipients. AlloSure is designed to check for cell-free DNA associated with organ rejection, a serious problem with kidney transplants. AlloSure is currently responsible for 83% of CareDx, Inc's total revenue.

CareDx, Inc reported that its annual Total Revenue rose from $48.32 million in 2017 to $76.56 million in 2018 and that its Net Loss declined from $55.46 million in 2017 to $46.75 million in 2018.

On July 16, 2019, a report noted that the AlloSure test manufactured by CareDx isn't nearly as popular as it seems because it misses around 40% of organ rejections compared to the current standard of care.